Gossamer Bio (GOSS) Income from Continuing Operations (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Income from Continuing Operations of 50082000.0 for Q1 2026, down 27.56% year-over-year from 69134360.59 in Q1 2025, and down 6.02% quarter-over-quarter from 47238000.0 in Q4 2025.
Gossamer Bio (GOSS) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Gossamer Bio's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 50082000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 27.56% year-over-year to 50082000.0; the TTM figure through Mar 2026 stood at 183814000.0 (down 241.29% YoY), while the FY2025 annual figure was 170370000.0, down 201.39% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 50082000.0, down from 47238000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 49267000.0 in Q2 2024, with the low at 59031000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 47238000.0 (2025), against an average of 40944882.35.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 215.93% in 2024, then slumped 177.68% in 2025.
- Gossamer Bio's Income from Continuing Operations stood at 58133000.0 in 2022, then advanced by 17.18% to 48148000.0 in 2023, then soared by 31.4% to 33029000.0 in 2024, then plunged by 43.02% to 47238000.0 in 2025, then dropped by 6.02% to 50082000.0 in 2026.
- Business Quant data shows GOSS's Income from Continuing Operations at 50082000.0 in Q1 2026, 47238000.0 in Q4 2025, and 48221000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -28.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.59 Mn |
| Mar 31, 2026 | -50.08 Mn |
| Dec 31, 2025 | -47.24 Mn |
| Sep 30, 2025 | -48.22 Mn |
| Jun 30, 2025 | -38.27 Mn |
| Mar 31, 2025 | -39.26 Mn |
| Dec 31, 2024 | -33.03 Mn |
| Sep 30, 2024 | -30.84 Mn |
| Jun 30, 2024 | 49.27 Mn |
| Mar 31, 2024 | -44.74 Mn |
| Dec 31, 2023 | -48.15 Mn |
| Sep 30, 2023 | -40.01 Mn |
| Jun 30, 2023 | -42.50 Mn |
| Mar 31, 2023 | -50.86 Mn |
| Dec 31, 2022 | -58.13 Mn |
| Sep 30, 2022 | -59.03 Mn |
| Jun 30, 2022 | -57.39 Mn |
| Mar 31, 2022 | -57.59 Mn |
| Dec 31, 2021 | -56.64 Mn |
| Sep 30, 2021 | -60.36 Mn |